

Guideline

Tunnelled central venous catheters

1. Purpose

This guideline has been developed as part of the I-Care intervention bundle for the management of intravascular devices (IVDs). This guideline provides recommendations regarding best practice for the use and management of invasive devices based on current evidence for the prevention and control of healthcare associated infection (HAI).

2. Scope

This guideline provides information for all employees, contractors and consultants within the Hospital and Health Services, divisions and commercialised business units within the Queensland public health system.

3. Related documents

Authorising policy and standard/s:

- [NSQHS Standard 3 – Preventing and Controlling Healthcare Associated Infections](#)

Standards, procedures, guidelines

- [Australian guidelines for the prevention and control of infection in healthcare](#)
- [Guideline for surveillance of healthcare associated infection](#)
- [Hand hygiene guideline](#)

Forms, templates

- [Tunnelled central venous catheter: maintenance – Point of care tool](#)

4. Guideline for tunnelled central venous catheters

Contents

Key critical points	3
General recommendations	3
Education and competency assessment.....	3
Hand hygiene.....	4
Surveillance.....	4
Insertion and management requirements	4
Insertion location.....	4
Catheter types and materials.....	4
Prophylactic antibiotics.....	5
Catheter site selection.....	5
Maximal barrier precautions.....	6
Skin preparation: insertion site.....	6
Dressing type and replacement intervals.....	7
Catheter fixation.....	8

Dressings: skin preparation.....	9
Chlorhexidine bathing.....	9
CVC review	9
Catheter duration and replacement.....	10
Guide-wire exchange	10
In-line filters.....	10
Flushing and locking of CVCs	10
General information.....	10
Flushing of CVCs	11
Locking of CVCs	11
IV admixtures	12
Replacement of IV fluids	12
Administration set changes	12
Blood components.....	13
Disconnection of administration sets.....	13
Medication labelling.....	13
Needleless access ports	13
Management of infected tunnelled catheters.....	14
Blood culture collection for diagnosis of BSI	15
Culturing of CVC tips.....	16
Ethanol lock therapy.....	17
Removal of tunnelled catheters.....	18
References	19
Bibliography.....	25

Key critical points

- Only competent staff (or training staff supervised by competent staff) are to insert Tunnelled Central Venous Catheters (CVC).
- Accurate documentation and record keeping should be maintained to ensure patient safety.
- IVD requirements should be constantly reassessed and any non-essential intravenous devices should be promptly removed.

General recommendations

- The clinician should choose an appropriate Intravascular Device (IVD) – consider catheter type, number of lumens, length, type of therapy, site of insertion, risk of complications including infection, and patient factors.⁽¹⁾
- Only competent staff (or training staff supervised by competent staff) should insert IVDs to minimise infection and other complications.^(1, 2)
- The clinician should explain to the patient (if possible) or parent/guardian the procedure and need for catheterisation.
- Environmental control measures (e.g. pulled curtains, closed door) should be taken to eliminate environmental risk factors for all procedures involving CVCs.⁽²⁾
- All sterile fields should be set up immediately prior to any procedure by the clinician or suitably trained assistant.
 - Trolleys/carts that include all necessary supplies should be dedicated for CVC insertion.^(3, 4)
- Accurate documentation and record keeping should be maintained by the clinician to ensure patient safety, to allow for audits, and to track outbreaks of infection. The documentation should include the date and time of insertion including type of IVD, gauge, length of line on insertion and removal, anatomical site, skin preparation solution used, name of operator, site observations and device removal/replacement details.^(5, 6)

Education and competency assessment

All clinicians involved in the insertion and maintenance of IVDs must ensure that this is within their scope of clinical practice, determined by the individual's credentials, education, training, competence and maintenance of performance at an expected level of safety and quality. The clinician's scope of practice is also dependent upon the capacity and capability of the service in which they are working.^(7, 8)

- All staff involved in the insertion and maintenance of IVDs should complete all competency assessments as required by the healthcare facility. A record of this should be maintained by the facility.^(1, 3, 4, 6, 9-15)
- Simulation training of catheter insertion procedures including infection prevention strategies has been shown to be successful in reducing rates of Central Line Associated Bloodstream Infection (CLABSI).^(3, 15-17)
- A proportion of patients will be responsible for their own catheter care when discharged from hospital in between treatment regimens. It is recommended that patients be provided with theoretical and practical training by a clinician.^(10, 12, 14, 18) This should include step-by-step instructions in text and images, of clinical procedures needed for care, including principles and techniques i.e. hygiene, dressing changes, flushing techniques and manipulation of the

catheter.^(5, 13) Where possible, controlled testing of the patient's knowledge as well as their practical execution of the techniques should be undertaken.

Hand hygiene

- It is recommended that healthcare workers perform hand hygiene with an antiseptic-containing soap solution or use an alcohol-based waterless cleanser:
 - before and after palpating catheter insertion sites
 - before and after accessing, repairing, or dressing an intravascular catheter; this includes associated components such as administration sets and access ports.^(1, 3, 4, 12-15, 18-22)
- The use of gloves does not obviate the need for hand hygiene.
- It is recommended that the clinician educate patients and carers about the importance of hand hygiene and ask that they remind all caregivers to clean their hands.⁽²⁾

Surveillance

It is recommended that surveillance be conducted in high-risk patient populations by a facility appointed person to determine healthcare associated (HCA) IVD-related Bloodstream Infection (BSI) rates, monitor trends in rates and assist in identifying lapses in infection control practices.

- A facility-appointed person should:
 - report HCA IVD-related BSIs at least monthly to all stakeholders
 - investigate all clusters of HCA IVD-related BSIs for common cause problems
 - investigate all episodes of HCA IVD-related *Staphylococcus aureus* BSI using an Investigation Checklist e.g. The *Staphylococcus aureus* BSI Checklist available from: <https://www.health.qld.gov.au/publications/clinical-practice/guidelines-procedures/diseases-infection/infection-prevention/icare-bsi-checklist.pdf>.
- The introduction of new products or processes should be monitored to identify any increase or decrease in the occurrence of device associated infection.⁽²⁾

Insertion and management requirements

Insertion location

It is recommended that:

- Imaging facilities (fluoroscopy, intravenous contrast studies and standard radiography) should be available for the insertion of tunnelled central venous catheters (CVC).^(1, 23, 24)
- Tunnelled CVCs should be inserted by a clinician in an area where sterile conditions can be maintained (e.g. interventional radiology suite, surgical operating room) and where the patient can be monitored (i.e. ECG and pulse oximetry).
 - Radiologic insertion, in both adult and paediatric populations, has been found to increase procedure success, decrease acute complications, and result in long-term safety comparable with or better than that achieved by surgical insertion.^(1, 23-28)
- A chest x-ray should be performed post-CVC insertion. A further chest x-ray will be required if the patient becomes dyspnoeic or complains of lateral chest wall discomfort.^(23, 24)

Catheter types and materials

- Catheter choice should be based on local experience, goals for use, and cost.⁽²⁾

- The minimum necessary number of lumens, connectors and ports should be used.^(1, 6, 11, 14, 29-31)
- If total parenteral nutrition is being administered, clinicians should utilise one lumen exclusively for that use.^(14, 29)
- Clinicians should use the smallest diameter catheter possible to minimise the risk of catheter-related thrombosis and/or subsequent venous stenosis.
 - Triple-lumen catheters have been reported to show an increase in technical difficulties along with an apparent increase in complication rates; therefore place these larger catheters only if absolutely indicated e.g. stem cell transplantation or chemotherapy where a number of agents and blood products require simultaneous infusion.
- Heparin-coated catheters are not recommended.
- There is evidence supporting the use of antimicrobial coated or impregnated catheters to reduce catheter colonisation and associated bloodstream infection.^(1, 11, 32) Further clinical trials are required to determine the benefits of these catheters in terms of overall patient morbidity and mortality before they can be recommended across all settings.⁽³³⁻³⁶⁾ The overall benefits of antimicrobial-impregnated CVCs are uncertain and therefore caution should be exercised before considering the use of these catheters across all settings.^(3, 11, 15, 37)
 - It is recommended that an antiseptic-impregnated CVC be considered by clinicians for adults whose catheter is expected to remain in place > 5 days if, after implementing a comprehensive strategy to reduce rates of CVC-related BSI, the CVC-related BSI rate remains above the goal set by the individual institution based on benchmark rates and local factors.^(1, 14, 30, 31)

Prophylactic antibiotics

- Prophylactic antibacterial or antifungal agents (oral, intranasal or parenteral) are not recommended for routine use at the time of insertion or during use of a CVC to prevent catheter colonisation or bloodstream infection.^(3, 11, 14, 15, 30, 31)
- Anti-infective/microbial lock prophylaxis - additional studies are required before antimicrobial lock solutions instilled into the catheter lumen(s) can be recommended for preventing BSIs due to concerns of toxicity and emergence of antimicrobial resistance.^(11, 14, 26, 30, 38-42)

Catheter site selection

- Clinicians should assess specific patient factors such as previous procedures, underlying medical problems, anatomic deformity, site restrictions, the relative risk of mechanical complications and the risk of infection.⁽¹⁴⁾
- The subclavian, internal jugular⁽³⁰⁾ and femoral veins can be used.
 - For all three venous access sites, the right side of the patient is usually favoured because vessel anatomy allows direct access to the superior vena cava/inferior vena cava and provides the shorter and easier route for the practitioner inserting the device.
 - Lower infection rates have been reported with the subclavian approach compared to the femoral and internal jugular veins, however, catheters placed via the subclavian vein are more likely to cause thrombosis.^(24, 25, 38)
 - Subclavian vein catheterisation should be avoided for temporary access in all patients with chronic renal failure due to the risk of central vein stenosis.^(1, 12, 43)
 - A low right internal jugular access has the least likelihood to develop catheter dysfunction, venous stenosis or occlusion.^(20, 25)

- Catheters may be inserted into a femoral vein, although infection rates and rates of deep vein thrombosis are higher.^(15, 38)
- The use of ultrasound and image guided placement of CVC can reduce mechanical complications compared with the standard landmark placement technique.^(1, 15, 23-28, 44, 45)

Maximal barrier precautions

Before placing a CVC (including guide-wire exchanges), it is recommended that the operator and any person who enters the sterile field to assist in the procedure should use maximal barrier precautions including a cap, mask, sterile gown, sterile gloves, and a sterile full body drape.^(1, 3-5, 11, 13-15, 21, 26, 29-31)

- The patient's hair should be entirely covered with a surgical cap.
- Place surgical cap on head to cover all hair, then don protective eyewear and surgical mask.
- CVC insertion requires surgical aseptic technique⁽²⁾ and therefore a surgical scrub should be performed prior to the procedure.⁽⁴⁶⁾
- Aseptically don sterile long-sleeved gown.
- Aseptically don sterile surgical gloves (ensure gloves cover cuff of gown).
- Prep catheter insertion site, allow to dry (refer: [Skin preparation: insertion site](#)).
- Drape the entire body of the patient (while maintaining a sterile field) with a large sterile fenestrated drape leaving only a small opening at the insertion site. The wide arc of the guide-wire and the subsequent need to control its free end require adequate draping well beyond its radius.

Skin preparation: insertion site

It is recommended that:

- Hair at the insertion site should only be removed by clinicians (prior to antiseptic application), using clippers (not shaved) to improve adherence of the dressing.^(5, 29)
- The skin should be physically cleaned (if necessary) by the clinician prior to applying the antiseptic solution and inserting the catheter.
- Removal of skin lipids (defatting) by the clinician with alcohol, ether or acetone is not recommended.⁽²⁹⁾
- Use alcohol-containing skin preparatory agents if no contraindication exists. The most effective disinfectant (chlorhexidine or povidone iodine) to combine with alcohol has not been established in the literature (be aware that either agent may be contraindicated e.g. sensitivity, allergy)
 - A solution containing 2% chlorhexidine gluconate (CHG) in $\geq 70\%$ (ethyl or isopropyl) alcohol (alcoholic chlorhexidine) should be used by clinicians for preparation of the insertion site.^(5, 22, 47)

or

- A solution containing povidone-iodine 10% in 70% ethyl alcohol (ethanol)⁽⁴⁸⁾ (povidone-iodine should remain on the skin for at least two minutes and until dry before inserting the catheter).
 - Non-sterile antiseptic applicators (e.g. swabsticks) should not be placed on the sterile field. Antiseptic liquid solutions are able to be poured into a sterile pot on the sterile field.⁽²⁹⁾
 - If using non-sterile antiseptic applicators, skin preparation should be undertaken by an alternative staff member who is not gowned and gloved to insert the line.

Tunnelled central venous catheters

- If alcohol is contraindicated (e.g. allergy, sensitivity, skin condition) clinicians should use aqueous povidone-iodine⁽⁴⁹⁾ 10%* or sterile normal saline 0.9% (*NB: the drying time for aqueous based antiseptics is longer than alcohol based products).
- Note: The same antimicrobial agent shall be used for all phases of the patient's skin preparation, to ensure full residual benefit and consistent action.⁽⁵⁰⁾
- 70% alcohol solution (including alcohol-impregnated swabs) should not be used as it has no residual antimicrobial activity on the skin.
- The solution should be applied vigorously by the clinician to an area of skin approximately 30cm in diameter, in a circular motion beginning in the centre of the proposed site and moving outward, for at least 30 seconds.⁽⁵⁾
 - This step should be repeated a total of three times using a new swab for each application.
- The clinician should allow the antiseptic to air dry completely prior to inserting the catheter; do not wipe or blot.⁽¹⁾
- Clinicians should not palpate the insertion site after the application of antiseptic, unless aseptic technique is maintained.^(1, 12)
- Clinicians should not routinely use antimicrobial ointments or creams under the dressing at the insertion site.^(1, 11, 13-15, 29-31)
- The length of the line used should be noted prior to insertion and clearly documented in the patient's notes.⁽⁵⁾

Dressing type and replacement intervals

- Tunnelled catheter dressings should be changed 24 hours after insertion^(6, 51, 52) and as below:

Table 1: Dressing types and replacement intervals

Dressing type	Replacement interval
Transparent, semi-permeable, self-adhesive polyurethane	Weekly ^{*(1, 3, 6, 12, 14, 15, 19, 21, 22, 25, 29-31, 51, 53)}
Gauze	Second daily ^{*(15, 31, 51)}
Chlorhexidine-impregnated	Weekly ^{*(1, 19, 21)}
*All dressings should be replaced routinely as well as when the dressing becomes damp, loosened, no longer occlusive or adherent, soiled, if there is evidence of inflammation, or excessive accumulation of fluid. Manufacturer's recommendations should be followed. ^(1, 3, 14, 15, 19, 21, 22, 29-31, 51)	

- For longer-term catheter maintenance in home patients, less frequent dressing changes may be possible depending on patient characteristics relating to perspiration and cleanliness. Semi-permeable dressings generally begin to degrade two weeks after application.
- Patient as well as environmental factors should be considered when selecting the most appropriate dressing for use on a percutaneous central venous catheter. The following recommendations should be considered:

- Transparent, semi-permeable, self-adhesive, (standard or hyperpermeable), polyurethane dressings.^(6, 14, 21, 26, 29, 51, 53-55)
 - Benefits include protecting the site from extrinsic contamination, allowing continuous observation of the insertion site, and helping stabilise and secure the catheter.^(6, 29, 55)
 - The clinician should inspect the dressing on the exit site daily.⁽²²⁾
- Sterile gauze dressing secured with adhesive tape or semi-permeable dressing.^(21, 51, 53-55)
 - If gauze is used in combination with a semi-permeable dressing, it is considered a gauze dressing and should be changed every 48 hours.^(1, 3, 6, 15, 19, 29)
 - Gauze dressings should only be used by clinicians if there is a true contraindication to polyurethane dressings including diaphoresis or excessive ooze from the insertion site and should be replaced by a transparent dressing as soon as possible.^(14, 29)
- Chlorhexidine-impregnated dressings and sponges have been shown to reduce the risk of exit site infection⁽⁵⁶⁾ and catheter-related bacteraemia.^(12, 14, 15, 25, 26, 29, 31, 57-59)
 - The safety of chlorhexidine-impregnated dressings/sponges has not been established in low birth weight neonates who may be at risk of skin or systemic toxicity.
- The dressing (including polyurethane types) should not be immersed or submerged in water.⁽¹⁾
 - Showering is preferable to bathing, and swimming or spa bathing should be avoided with any external catheter,⁽³⁰⁾ in order to prevent colonisation with Gram negative organisms, especially *Pseudomonas* spp.
- Clinicians should utilise an aseptic technique^(6, 14, 51) including sterile dressing (or dressing change) pack with drape and sterile gloves when changing the dressing on a CVC:
 - if the patient is coughing or cannot turn their head away from the exit site, consider having them wear a face mask.
- Clinicians should dress each catheter as a separate procedure.
- Tunnelled catheters that are well healed (following adherence of the cuff, usually within three weeks of insertion) may not require dressings.^(14, 51) However, this should be reviewed on an individual basis; the line should remain looped and securely attached to the patient's chest to prevent accidental removal of the catheter.

Catheter fixation

- Suture at the insertion and anterior chest wall puncture sites.
 - The suture at the insertion site is usually removed at 7-10 days; the second suture at the exit site should be removed after three weeks.
- Sutureless securement device:
 - A sutureless securement device has been shown to be superior in reducing infection risk,^(15, 60) length of time required to secure the catheter to the skin and avoiding the additional risk of needlestick injury associated with suturing.⁽¹⁾
 - The potential for this device to reduce infection may derive from the elimination of skin suture wounds that are contiguous to the newly inserted catheter and from minimisation of the to-and-fro positioning of the catheter, which may promote invasion of the tract by cutaneous microorganisms through capillary action.^(1, 15, 61)
 - Sutureless securement devices should be used in accordance with manufacturer's instructions.

Dressings: skin preparation

- 2% alcoholic chlorhexidine is the preferred solution for skin preparation for dressings, however if contraindicated clinicians should use the same solution utilised for skin preparation prior to CVC insertion (refer: [Skin preparation: insertion site](#)).^(1, 3, 5, 6, 13, 14, 20-22, 24, 29, 30, 51, 53, 62-64)
- Most CVC and other catheter materials are generally alcohol-resistant, however alcohol can damage some types of polyurethane and silicone CVC tubing (refer to manufacturer's instructions).^(1, 5, 14)
- Removal of skin lipids (defatting) by clinicians with alcohol, ether or acetone is not recommended.⁽²⁹⁾
- Clinicians should remove blood or ooze from catheter insertion site with sterile 0.9% sodium chloride.
- Clinicians should cleanse the area (the size of the final dressing) around the catheter including under the hub.
- Cleansing should be performed using a circular motion moving in concentric circles from the site outward.
 - Clinicians should repeat this step a total of three times using a new swab for each application.⁽¹⁾
- Clinicians should apply the antiseptic solution vigorously for at least 30 seconds and allow to air dry; do not wipe or blot.
- Clinicians should not use antimicrobial ointments or creams under the dressing at the insertion site.^(1, 11, 13, 14, 21, 29)

Chlorhexidine bathing

For information regarding chlorhexidine bathing please refer to appendix two of the [CHRISP guideline for the management of multi-resistant organisms](#).

CVC review

- CVCs should be reviewed each shift by clinicians, and those that are no longer clearly needed should be promptly removed.^(1, 3, 4, 12, 13, 22, 29-31)
 - Insertion site
 - The insertion site should be examined daily by the clinician⁽²²⁾ (or at each dressing change if gauze is used) for erythema, exudate, tenderness, pain, redness, swelling, suture integrity and catheter position.^(6, 15)
 - Signs of systemic infection
 - Site appearance should not be used as the only indicator of infection. Local inflammation is uncommon with CVC-related infection caused by coagulase-negative staphylococci as this pathogen incites little local or systemic inflammation. The patient should also be examined for fever or other signs of sepsis e.g. tachycardia, tachypnoea, hypotension.
 - Patency of lumens⁽²⁹⁾
- Patients should be encouraged (where possible) by clinicians to report any changes in their catheter site or any new discomfort.

Catheter duration and replacement

- The CVC should only be replaced on clinical indications i.e. clinical infection +/- purulence at the insertion site.^(1, 11, 15)
- CVCs should not be routinely replaced.^(14, 15)
- Patients transferring from other healthcare facilities with a CVC *in situ* should have this device reviewed upon arrival by a clinician for infectious and mechanical complications.
- Clinicians should continually review the need for central venous access in individual patients.^(1, 22, 29)
- Clinicians should replace all fluid administration tubing and connectors when the CVC is replaced.^(1, 21, 65)

Guide-wire exchange

- Guide-wire-assisted catheter exchange is not advised for cuffed tunnelled catheters when it may be technically easier and safer to insert a new catheter into a clean site.

In-line filters

- In-line filters are not recommended for infection control purposes, however certain chemotherapeutic and immunological drugs require filtering for other reasons.⁽⁵⁾
 - Lines containing filters should be removed immediately following administration of the drug.

Flushing and locking of CVCs

General information

- Where possible, continuous intravenous fluids should be administered by a clinician using an infusion pump.
- The optimal volume and frequency of flushing and/or locking of catheters for intermittent injections or infusions is unclear.
 - The literature suggests the volume of the flush or lock should equal at least twice the volume of the catheter plus add-on devices (if used).^(5, 19)
 - The catheter should be locked using the volume of solution recommended by the manufacturer (the volume is generally printed on the hub or lumen of the catheter).
 - If using heparin lock, the volume should not exceed the recommended amount to avoid systemic heparinisation of the patient.
- Only single-dose solutions should be used by clinicians.⁽⁵¹⁾
- Clinicians should use a syringe with the internal diameter of a 10mL syringe (or larger), to avoid excessive pressure and catheter rupture (the diameter of 10mL syringes varies slightly between manufacturers but is usually around 14.5-15.5mm). Syringes with an internal diameter smaller than that of a 10mL syringe can produce higher pressure in the lumen and rupture the catheter).^(19, 51)
 - Infusion pressure should never exceed 25 psi because pressures higher than that may also damage blood vessels.
 - The internal diameter of a standard 3mL syringe generates pressure greater than 25 psi, whereas a syringe with the internal diameter of a 10mL syringe generates less than 10 psi.⁽⁶⁾

- 3mL syringes with the internal diameter of a 10mL syringe do not produce higher pressure and are acceptable for use.
- Clinicians should flush in a pulsatile (push-pause or start-stop-start) motion.^(6, 19, 51, 66)
- Clinicians should use an aseptic technique⁽⁶⁾ including meticulously cleaning the access port(s) with a single-use 70% alcohol-impregnated swab or alcoholic chlorhexidine and allowing to dry prior to accessing the system.^(3, 19, 51)
- Disconnecting the flush syringe allows reflux of blood into the tip of the catheter to displace the space occupied by the syringe. To prevent this source of occlusion, the clinician should clamp the extension set or withdraw the syringe while administering the last 0.5mL of flush (positive pressure technique).^(6, 10, 19, 51, 66)
- Positive- or negative-pressure mechanical valve needleless connectors have been associated with increases in rates of catheter-related bacteraemia and therefore are not recommended for use.^(29, 67-69) Refer: [Flushing of CVCs](#).

Flushing of CVCs

- Flushing is recommended to promote and maintain patency and prevent the mixing of incompatible medications and solutions.
- Sterile 0.9% sodium chloride for injection should be used by clinicians to flush a catheter unless the manufacturer recommends flushing with heparin sodium solution.⁽¹⁴⁾
- Clinicians should flush catheters immediately:
 - after placement
 - prior to and after fluid infusion or injection (as an empty fluid container lacks infusion pressure and will allow blood reflux into the catheter lumen from normal venous pressure)
 - prior to and after blood drawing.
- The flush solution and flushing intervals should be documented by the clinician in the patient record.

Locking of CVCs

- If it is necessary to lock a CVC the following recommendations should be considered by the clinician:
 - Locking involves instilling a solution to prevent occlusion when the device is not in use.
 - There is limited information concerning the most appropriate solution to lock a catheter. Heparinised saline has been used primarily due to the antithrombotic properties of heparin. However, complications such as heparin-induced thrombocytopenia (HIT), altered coagulation studies and bleeding have been reported, particularly if other general anticoagulant therapy is administered.^(20, 24, 70) Additionally, heparin is incompatible with certain substances in solution e.g. gentamicin sulphate (refer to MIMS Online available from: <https://www.mimsonline.com.au/Search/Search.aspx>).
 - For CVCs not in regular use, in adults, sterile 0.9% sodium chloride for injection should be used by clinicians to lock a catheter in preparation for future use, unless the manufacturer recommends catheter lumens be locked with an alternate solution.
 - The most important part of locking the catheter is the mechanical action of the procedure itself, designed to prevent backflow of blood into the catheter tip i.e. 'pulsatile' and 'positive pressure' flushing techniques.^(6, 19, 51, 66)

- Some CVCs integrate valve technology which restricts blood backflow and air embolism by remaining closed when not in use⁽³⁰⁾ therefore eliminating the need for heparin flushing to maintain patency.
- Low-dose oral warfarin or other systemic anticoagulants should not be prescribed for prophylaxis of catheter occlusion.^(11, 13, 14)

IV admixtures

It is recommended that:

- Clinicians should admix all intravenous fluids using an aseptic technique.⁽¹⁴⁾
- Clinicians should not use containers of intravenous fluid that have visible turbidity, leaks, cracks or particulate matter, or if the manufacturer's expiration date has passed.
- Clinicians should use single-dose vials for parenteral additives or medications when possible.
- Clinicians should use the recommended needle gauge for injecting additives into infusion bags and/or burettes.⁽⁵⁾

Replacement of IV fluids

Table 2: IV fluid replacement intervals

Fluid	Replacement interval
Standard (crystalloid) and non-lipid parenteral solutions	Every 24 hours
Lipid-containing solutions	Within 24 hours
Lipid emulsions	Within 12 hours
All blood components (excluding factor VIII or IX for continuous infusion)	Within 4 hours
Drug infusions (e.g. heparin, insulin)	Every 24 hours ^(5, 21, 71)

- When any IVD is resited, it is recommended that both the infusion and administration set be replaced by the clinician regardless of when the infusion was initially commenced.⁽²⁹⁾
- IV administration sets should be spiked into IV fluid bags the whole way.⁽⁷²⁾
- Each bag of IV fluid should only be spiked once.⁽⁷³⁾
- It is recommended that all IV fluids be stored by facilities according to manufacturer's guidelines.
- It is recommended that bags or bottles of intravenous solution should not be used as a common source of supply for multiple patients.⁽²⁾

Administration set changes

It is recommended that:

- Clinicians should ensure all components of the administration system are compatible (this includes burettes), including needleless intravascular devices to minimise leaks and breaks in the system.
 - Add-on equipment should be of luer-lock design.⁽⁵⁾

Table 3: Administration set replacement intervals

Administration set	Replacement interval
Not containing lipids, blood or blood products	Up to 96 hours ^{*(3, 5, 14, 52)}
Lipid/lipid-containing parenteral nutrition	Within 24 hours ^{*(1, 14, 21, 29, 52, 65)}
Chemotherapeutic agents	Remove immediately after use*
Propofol	Within 12 hours or as per manufacturer ^{*(1, 5, 52)}
Heparin	Every 24 hours ^(5, 21, 71)
Other infusions (not including blood products)	When disconnected or new catheter ^{*(29)}
*All administration sets should be replaced when disconnected or if the catheter is changed ^(1, 21, 29, 65) When an administration set is changed, the IV fluid bag should also be changed. ⁽⁷³⁾	

Blood components

- Must be transfused using an administration set approved for this purpose, incorporating a standard filter which removes clots and small clumps of debris that may form during collection and storage. The recommended filter pore size is 170-200 micron.^(5, 71)
- Any number of red cell units may be transfused during a 12-hour period provided the flow rate remains adequate. However specific manufacturer's recommendations defining the maximum number of units per blood administration set must not be exceeded.⁽⁷¹⁾ Administration sets should be removed by the clinician immediately after use.^(14, 22)

Disconnection of administration sets

- Administration sets should not be intermittently disconnected (including for patient showering/toileting).⁽²⁾
- If administration sets are disconnected from the intravascular device, the set should be discarded and a new administration set connected using aseptic technique and observing standard precautions.
- Intermittent disconnection of administration sets increases risk of infection through manipulation of the hub and contamination, and occlusion due to reflux of blood into the catheter tip.^(5, 10, 29)

Medication labelling

- It is recommended that clinicians abide by labelling recommendations for all injectable products prepared in the ward or clinical area, including recommendations for labelling containers (bags, bottles and syringes) and conduits (lines and catheters).^(5, 74)
- It is recommended that clinicians ensure labelling complies with the national recommendations for user-applied labelling of injectable medicines, fluids and lines (current edition) as set out by [The Australian Commission on Safety and Quality in Healthcare](#).

Needleless access ports

- Clinicians should minimise catheter manipulation (e.g. number of intermittent infusions).⁽⁵²⁾
- Closed catheter access systems are associated with fewer CRBSIs than open systems.⁽¹⁾ Therefore, needleless access ports should be used on all lumens.
 - Stopcocks should be end-capped with a needleless access port/cap when not in use.^(1, 26)

- All persons handling or accessing the intravascular system should first perform hand hygiene.^(22, 29-31, 51)
- Needleless access ports should be used by clinicians according to manufacturer's recommendations.
- Clinicians should not use adhesive tape as a means of junction securement between the hub and connector or infusion line.
- All intravenous access ports should be meticulously cleaned by the clinician with a single-use 70% alcohol-impregnated swab or 2% alcoholic chlorhexidine vigorously for a minimum of 15 seconds and allowed to air dry prior to accessing the system.^(5, 14, 51) For example a typical intermittent infusion of medication may involve swabbing the access port:
 - before the initial saline injection to assess catheter patency,
 - before attaching the sterile infusion tubing or syringe, and
 - before flushing and/or locking the catheter with saline after administering the medication.
- The catheter should be accessed by the clinician with a sterile single-use device.
- Anytime an access port is removed from a catheter, the clinician should discard it and a new sterile access port should be attached.
- The integrity of the access port should be confirmed by the clinician before and immediately after each use. If the integrity of the access port is compromised or if residual blood remains within the access port, it should be replaced immediately and consideration given to changing the administration set.⁽⁵⁾
- Needleless access ports should be changed as per manufacturer's instructions or if the integrity of the port is compromised.⁽⁵⁾ In general, a lot of manufacturers recommend that their needleless components be changed weekly or when there are signs of blood, precipitate, leaks or other defects.⁽⁵¹⁾
 - CDC guidelines currently recommend that needleless components be changed at least as frequently as the administration set, but no more frequently than every 72 hours.⁽¹⁾ A recent study has identified an increased CLABSI rate when needleless access ports were changed every 24 hours with lines containing blood products or lipids.⁽⁷⁵⁾
 - More frequent changing of access ports may reduce the burden of access port contamination that could lead to bloodstream infection, however more frequent manipulation of the catheter for access port changes could increase the risk of infection.⁽⁷⁵⁾
- Clinicians can use central venous catheters for blood sampling; it is advisable to follow manufacturers' instructions as to the best practise for their device. With some devices it is advisable to limit or avoid this practice because of the increased risk of occlusion (clotting) and infection in the catheter from any residual blood;^(24, 76) if necessary clinicians should minimise blood sampling by batching laboratory specimen draws.⁽⁵²⁾

Management of infected tunnelled catheters

Definitions-Refer: [Definition of terms](#)

General management recommendations:

- Accurate and early diagnosis of infection is essential. Clinicians should monitor for signs of infection including erythema, pain, exudate, heat, tenderness, swelling and systemic signs of sepsis.

- Blood cultures should be promptly collected by clinicians on suspicion of catheter-related BSI.
- The management of catheter-related infection depends on a number of factors including:^(10, 11, 15)
 - patient factors
 - the type of organism involved
 - the requirement for the CVAD
 - the type of infection.
- Catheter removal is not always feasible (e.g. absence of other vascular access sites).⁽¹⁵⁾ In such cases, intravenous antimicrobial therapy may be required for longer periods.⁽¹¹⁾
- Exit site infections without clinical or microbiological evidence of BSI may be able to be treated with catheter retention and local exit site care with or without systemic antibiotic therapy.^(15, 20, 77)
- Tunnel infections usually require catheter removal⁽¹²⁾ and systemic antibiotic therapy,⁽¹⁵⁾ and may involve excision of the tunnel site.^(3, 24, 38)
- Catheter-related BSIs require prompt initiation of empiric systemic antibiotic therapy, subsequent modification of antibiotic therapy based upon microbiological results, consideration of catheter removal, and investigation for metastatic infective complications (e.g. endocarditis).^(15, 38, 56)
- In some situations the use of ethanol lock therapy can preserve a CVC. (Refer: [Ethanol lock therapy](#))
- The duration of antibiotic therapy depends upon clinical response, culture results, and the presence of metastatic infective complications.⁽⁶³⁾

Blood culture collection for diagnosis of BSI

Refer to local hospital procedure for blood culture collection and [Pathology Queensland and CHRISP Recommendations for Blood Culture Collection – Adults](#) (Queensland Health Intranet access only).

It is recommended that:

- Blood cultures should always be collected by a clinician from a peripheral vessel.
 - Approximately 20mL is required and 10mL should be placed in each of the anaerobic and aerobic blood culture bottles.^(76, 78, 79)
 - Staff should read the instructions on the blood culture bottle as different blood culture systems have different requirements.
 - Each anaerobic and aerobic bottle constitutes a blood culture 'set'. No more than three sets are required in one episode. Two sets has a sensitivity of >90% while collecting three sets will increase that to >98%.^(24, 80)
- 10mL draws are suggested for each bottle. There is no need to collect more than two bottles per lumen.⁽⁷⁶⁾
- Taking blood cultures through a CVC is discouraged as the practice may cause occlusion and contribute to catheter lumen colonisation.^(24, 76)
- Blood for culture should only be collected from a CVC in addition to peripheral blood where:
 - there is no other access available, or
 - following placement of a new CVC and only by the operator, or

- attempting to determine if the catheter (lumen) is contaminated.^(15, 41, 77)
- If catheter-related bloodstream infection is suspected:
 - the clinician should use strict aseptic technique and hand hygiene prior to blood culture collection to reduce the risk of microbial contamination⁽⁸¹⁾
 - the clinician should utilise sterile collection equipment
 - the clinician should use standard precautions when collecting blood cultures, including eye protection
 - Non-sterile gloves can be used in accordance with aseptic technique. If key parts or key sites are touched, sterile gloves should be used.⁽⁸¹⁾ If there is a high rate of contamination, routine sterile gloving and/or sterile blood culture kits have been shown to significantly decrease contamination rates.⁽⁸²⁻⁸⁴⁾ Cost vs benefit should be considered.^(81, 85)
 - the first sample is to be taken peripherally by the clinician; cleanse skin with alcoholic chlorhexidine or ≥70% alcohol^(81, 86-89) and allow to dry prior to venepuncture
 - additional specimens can be collected by the clinician from each lumen of the catheter as above.^(15, 31, 78, 79)
- The blood culture bottle diaphragm should be swabbed by the clinician with a single-use 70% alcohol-impregnated swab prior to inoculating the bottle.⁽⁸¹⁾
- There is no need for the clinician to change the blood culture collection needle between venepuncture and bottle inoculation⁽⁸⁰⁾ (careful skin preparation is a more important factor than changing needles in reducing contamination during blood culture collection).⁽⁷⁸⁾
- Catheter discard blood, arterial line blood, intravenous catheter blood, “left over” blood from blood gas or other analyses should not be used by the clinician for blood cultures. If further blood tubes are required for testing, they should be collected after the blood cultures are drawn.^(24, 80, 81)
- The collection site as well as the patient’s clinical and demographic data should be recorded on the request form by the clinician.⁽⁷⁶⁾

Culturing of CVC tips

- Routine culture of catheter tips is not recommended^(31, 77, 79) however, periodic sampling could be considered in the context of measuring the effectiveness of interventions. This should only occur in consultation with Infection Prevention and Control and the Microbiology Laboratory.
- Culture of vascular catheter tips may be useful in confirming the source of line related bacteraemia when performed concurrently with peripheral blood cultures. Depending on local laboratory practice, vascular catheter tips are only processed if there is an associated positive blood culture.⁽⁹⁰⁾ Consult with local laboratory.
- If pus is present at the insertion site, clinicians should swab the site prior to cleaning and send for culture.
- If catheter-related sepsis is suspected:
 - the clinician should clean the skin at the skin-catheter junction with alcoholic chlorhexidine and allow the solution to dry prior to catheter removal – this will minimise skin contamination of the catheter tip
 - the clinician should remove the catheter aseptically

- a segment of the tip of the catheter (optimum length 5cm) should be submitted.^(31, 77) The tip should be aseptically cut from the end of the catheter directly into a sterile specimen container.⁽⁷⁹⁾ Transport to laboratory as quickly as possible to prevent excessive drying.⁽⁹⁰⁾
- The clinician should ensure the site and type of catheter are noted on the request form as well as the required clinical and demographic data.⁽⁹⁰⁾

Ethanol lock therapy

Antibiotics may be ineffective in the treatment of infected central venous catheters. This is due to the formation of a biofilm on the internal lumen of the catheter.⁽⁴¹⁾ Biofilm prevents antibiotic penetration to the surface of the inner lumen of the catheter despite appropriate antibiotic therapy. Ethanol locks have been proven to be effective in treating catheter infections and prolonging the life of the central venous catheter.^(42, 63, 91, 92)

Recommendations regarding ethanol lock therapy:

- Commencement of ethanol lock therapy should only occur after the patient has been reviewed by the infectious diseases team and following discussion with the treating consultant.
- Ethanol lock therapy **should not** be used if:
 - the patient is unstable
 - the patient has an exit site or tunnel infection
 - the patient is pregnant or breast feeding
 - the patient has a *Staphylococcus aureus* bacteraemia, known multi-resistant organism present or fungaemia (including candidaemia).
- Ethanol lock therapy can be used if:
 - the patient is stable
 - the patient has a catheter-associated bloodstream infection
 - there is no evidence of exit site or tunnel infection
 - appropriate antibiotic therapy has been initiated
 - the infectious diseases team and treating consultant agree to commence treatment.
- Prescribing recommendations:
 - Ethanol installation volume and withdrawal volumes and sodium chloride 0.9% flushes including the frequency of locks should be ordered by an appropriate clinician on the patient medication chart.
 - The dwell time for an ethanol lock is four hours. The ethanol lock should be repeated daily by clinicians for 4-5 days.
 - The clinician should aspirate the instilled volume at the conclusion of the dwell time and record this in the patient chart.
 - The volume of ethanol to be instilled equals the volume of the lumen plus any connecting tubing. This volume is determined by the CVC type. Refer to the patient chart notes for the manufacturer and serial number of the inserted CVC. Refer to the manufacturer's reference tables for lumen volume.

- Dilution:
 - The clinician should draw up 3.5mL of alcohol 100% (ethanol) and 1.5mL sterile water for injection in a 10mL syringe (makes a total of 5mL of 70%).
 - The clinician should discard excess drug to leave the required volume for the catheter lumen volume.
 - The clinician should flush the CVC pre and post ethanol lock with sodium chloride 0.9%. Post flushing of the line should only occur after the alcohol volume has been withdrawn from the CVC at the conclusion of the four hour dwell time.
- Refer to [Flushing and locking of CVCs](#) for correct technique to access line.

Removal of tunnelled catheters

- Also refer to local hospital procedure for removal of tunnelled CVC.
- Indications for catheter removal include:
 - catheter-related infection
 - persistent catheter occlusion
 - catheter-related thrombus
 - damaged catheter
 - end of treatment.

It is recommended that:

- Removal should be undertaken by experienced personnel.
- Removal of a skin-tunnelled catheter requires local anaesthetic and minor surgical cut-down to remove the cuff if the catheter has been *in situ* for more than approximately three weeks.⁽⁹³⁻⁹⁶⁾
 - The clinician should position patient supine, if possible.^(5, 94)
 - The clinician should perform hand hygiene and don non-sterile gloves.
 - The clinician should clean site thoroughly with alcoholic chlorhexidine and allow to dry prior to removal of catheter.
 - Simple traction by the clinician can remove the catheter and cuff in catheters which have been in less than three weeks. Digital pressure should be applied by the clinician until haemostasis is achieved.⁽⁹⁴⁻⁹⁶⁾
 - Some target vessels cannot be compressed during CVC removal, therefore special precautions should be taken by the clinician to observe the patient after removal for signs and symptoms of bleeding.
 - Otherwise, a cut-down procedure (small incision) is used by the clinician to release/free the cuff prior to line removal.⁽⁹⁴⁻⁹⁶⁾ The incision is sutured and sutures should be removed after one week by a clinician.
 - Cover site with gauze and a transparent dressing; the dressing should be changed and the access site assessed every 24 hours by a clinician until the sutures are removed and the site epithelialized.
 - On removal the clinician should visually check the integrity of the line to ensure that the tip is present, the complete line has been removed and no breakage has occurred.
 - The removed line should be measured and its length documented and checked against the length documented on insertion.

References

1. O'Grady N, Alexander M, Burns L, Dellinger E, Garland J, Heard S, et al. Healthcare Infection Control Practices Advisory Committee (HICPAC). Guidelines for the prevention of intravascular catheter-related infections. 2011.
2. ACSQHC. Australian Guidelines for the Prevention and Control of Infection in Healthcare. National Health and Medical Research Council; 2010.
3. Marschall J, Mermel L, Fakih M, Hadaway L, Kallen A, O'Grady N, et al. Strategies to prevent central line-associated bloodstream infections in acute care hospitals: 2014 update. *Infection Control and Hospital Epidemiology*. 2014;35(7):753-71.
4. Sacks G, Diggs B, Hadjizacharia P, Green D, Salim A, Malinoski D. Reducing the rate of catheter-associated bloodstream infections in a surgical intensive care unit using the Institute for Healthcare Improvement central line bundle. *The American Journal of Surgery*. 2014;207(6):817-23.
5. Dougherty L, Bravery K, Gabriel J, Kayley J, Malster M, Scales K, et al. Standards for infusion therapy (third edition). Royal College of Nursing; 2010.
6. Ho A, Bravery K. Central venous access devices (long term). London: Great Ormond Street Hospital for Children NHS Foundation Trust. 2013.
7. Queensland Government. Health service directive # QH-HSD-034:2014 Credentialing and defining the scope of clinical practice. 2014.
8. ACSQHC. Standard for credentialing and defining the scope of clinical practice. Australian Commission on Safety and Quality in Health Care. 2004.
9. Teichgraber U, Pfitzmann R, Hofmann H. Central venous port systems as an integral part of chemotherapy. *Deutsches Arzteblatt International*. 2011;108(9):147-54.
10. Adams S, Barrett L, Brooks S, Dahler A, Jansens W, Shaw H. Central venous access devices: principles for nursing practice and education. Cancer Nurses Society of Australia; 2007.
11. Schiffer C, Mangu P, Wade J, Camp-Sorrell D, Cope D, El-Rayes B, et al. Central venous catheter care for the patient with cancer: American Society of Clinical Oncology Clinical Practice Guideline. *Journal of Clinical Oncology*. 2013;31(10):1357-70.
12. Bowe-Geddes L. Planning for and successfully managing long-term venous access devices. *Mosby's Nursing Consult*. 2013 Dec 20, 2013.
13. Camp-Sorrell D. State of the science of oncology vascular access devices. *Seminars in Oncology Nursing*. 2010;26(2):80-7.
14. Loveday H, Wilson J, Pratt R, Golsorkhi M, Tingle A, Bak A, et al. epic3: national evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. *Journal of Hospital Infection*. 2014(86S1):S1-S70.
15. Hentrich M, Schalk E, Schmidt-Hieber M, Chaberny I, Mousset S, Buchheidt D, et al. Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology. *Annals of Oncology*. 2014;25(5):936-47.
16. Allen G, Miller V, Nicholas C, Hess S, Cordes M, Fortune J, et al. A multitiered strategy of simulation training, kit consolidation, and electronic documentation is associated with a

- reduction in central line-associated bloodstream infections. *American Journal of Infection Control*. 2014;42:643-8.
17. Barsuk J, Cohen E, Potts S, Demo H, Gupta S, Feinglass J, et al. Dissemination of a simulation-based mastery learning intervention reduces central-line associated bloodstream infections. *BMJ Quality and Safety*. 2014;23:749-56.
 18. Lok C, Thumma J, McCullough K, Gillepsie B, Fluck R, Marshall M, et al. Catheter-related infection and septicemia: Impact of seasonality and modifiable practices from the DOPPS. *Seminars in Dialysis*. 2013;27(1):72-7.
 19. Nailon R, O'Neill S, Cowdery P, Wardian Hartung S, Tyner K, Tomb P, et al. Standardizing central venous catheter care: hospital to home. Rockville MD: Agency for Healthcare Research and Quality (AHRQ); 2012.
 20. Bholra C, Lok C. Central venous catheters: optimizing the suboptimal. *Nephrology News and Issues*. 2011 April 27, 2011.
 21. Zingg W, Cartier-Fassler V, Walder B. Central venous catheter-associated infections. *Best Practice and Research: Clinical Anaesthesiology*. 2008;22(3):407-21.
 22. McIntyre H, Raw A, Stephenson J, Bradley A, Dawson J, Fay M, et al. NICE quality standard 61: Infection prevention and control. National Institute for Health and Care Excellence; 2014.
 23. MacGinley R, Owen A. CARI Guideline: Insertion of catheters. Kidney Health Australia. 2012.
 24. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: haemodialysis adequacy, peritoneal dialysis adequacy and vascular access. *American Journal of Kidney Disease*. 2006;48(S1-S322).
 25. Polkinghorne K, Chin G, MacGinley R, Owen A, Russel C, Talaulikar G, et al. KHA-CARI Guideline: Vascular access - central venous catheters, arteriovenous fistulae and arteriovenous grafts. *Nephrology*. 2013;18:701-5.
 26. Rupp S, Apfelbaum J, Blitt C, Caplan R, Connis R, Domino K, et al. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists Task Force on Central Venous Access. *Anesthesiology*. 2012;116(3):539-73.
 27. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al. EBPg on Vascular Access. *Nephrology Dialysis Transplantation*. 2007 May 1, 2007;22(2):ii88-ii117.
 28. Troianos C, Hartman G, Glas K, Skubas N, Eberhardt R, Walker J, et al. Guidelines for performing ultrasound guided vascular cannulation: recommendations of the American Society of Echocardiography and the Society of Cardiovascular Anesthesiologists. *Journal of the American Society of Echocardiography*. 2011;24(12):1291-318.
 29. Australian and New Zealand Intensive Care Society (ANZICS). Central line insertion and maintenance guideline. Australian Commission on Safety and Quality in Health Care. 2012 April 2012.
 30. Smith R, Nolan J. Central venous catheters. *BMJ*. 2013;347:28-32.
 31. Cameron J, Cameron A. Central line-associated bloodstream infections. In: Cameron C, Cameron A, editors. *Current Surgical Therapy*, eleventh edition. Philadelphia, PA: Saunders; 2014.

32. Novikov A, Lam M, Mermel L, Casey A, Elliott T, Nightingale P. Impact of catheter antimicrobial coating on species-specific risk of catheter colonization: a meta-analysis. *Antimicrobial Resistance and Infection Control*. 2012;1(40).
33. Raad I, Mohamed J, Reitzel R, Jiang Y, Raad S, Shuaibi M, et al. Improved antibiotic-impregnated catheters with extended-spectrum activity against resistant bacteria and fungi. *Antimicrobial Agents and Chemotherapy*. 2012;56(2):935-41.
34. Jamal M, Rosenblatt J, Hachem R, Ying J, Pravinkumar E, Nates J, et al. Prevention of biofilm colonization by gram-negative bacteria on minocycline-rifampin-impregnated catheters sequentially coated with chlorhexidine. *Antimicrobial Agents and Chemotherapy*. 2014;58(2):1179-82.
35. Wang H, Huang T, Jing J, Jin J, Wang P, Yang M, et al. Effectiveness of different central venous catheters for catheter-related infections: a network meta-analysis. *Journal of Hospital Infection*. 2010;76:1-11.
36. Ramritu P, Halton K, Caollignon P, Cook D, Fraenkel D, Battistutta D, et al. A systematic review comparing the relative effectiveness of antimicrobial-coated catheters in intensive care units. *American Journal of Infection Control*. 2008;36(2):104-17.
37. Lai N, Chaiyakunapruk L, Lai N, O'Riordan E, Pau W, Saint S. Catheter impregnation, coating or bonding for reducing central venous catheter-related infections in adults (review). *The Cochrane Library*. 2013(6).
38. Vanholder R, Canaud B, Fluck R, Jadoul M, Labriola L, Marti-Monros A, et al. Diagnosis, prevention and treatment of haemodialysis catheter-related bloodstream infections (CRBSI): a position statement of European Renal Best Practice (ERBP). *NDT Plus*. 2010 June 1, 2010;3(3):234-46.
39. van de Wetering M, van Woensel J, Lawrie T. Prophylactic antibiotics for preventing gram positive infections associated with long-term central venous catheters in oncology patients (review). *The Cochrane Library*. 2013(11).
40. Natarajan S, Narayan S, Liu Yin J. Update on the management of febrile neutropenia. *European Oncology & Haematology*. 2011;7(4):263-9.
41. Schoot R, Dalen E, Ommen C, van de Wetering M. Antibiotic and other lock treatments for tunnelled central venous catheter-related infections, in children with cancer (review). *The Cochrane Library*. 2013(6).
42. Chaudhury A, Rangineni J, Venkatramana B. Catheter lock technique: in vitro efficacy of ethanol for eradication of methicillin-resistant staphylococcal biofilm compared with other agents. *Federation of European Microbiological Societies: Immunology & Medical Microbiology*. 2012;65:305-8.
43. Association for Vascular Access. Preservation of peripheral veins in patients with chronic kidney disease (position statement). 2011 14 March.
44. Association for Vascular Access. The use of ultrasound guidance by registered nurses for central venous catheter insertion (position statement). 2010 17 June.
45. Cartier V, Haenny A, Inan C, Walder B, Zingg W. No association between ultrasound-guided insertion of central venous catheters and bloodstream infection: a prospective observational study. *Journal of Hospital Infection*. 2014;87:103-8.
46. Grayson L, Russo P, K R, S H, K H. Five moments for hand hygiene. *Hand Hygiene Australia*. 2013.

47. NSW Ministry of Health. Guideline for Peripheral Intravenous Cannula (PIVC) insertion and post insertion care in adult patients. 2013.
48. Morris W, Tay M. Strategies for preventing peripheral intravenous cannula infection. *British Journal of Nursing*. 2008;17(19):S14-S21.
49. American Society of Anesthesiologists Task Force (ASA). Practice guidelines for central venous access. *Anesthesiology*. 2012;116(3):539-73.
50. Australian College of Operating Room Nurses (ACORN). 2014-2015. Standards for perioperative nursing.
51. Centers for Disease Control and Prevention (CDC). Basic infection control and prevention plan for outpatient oncology settings. Atlanta, GA: Division of Healthcare Quality Promotion (DHQP); 2011.
52. Davis M. Pediatric central venous catheter management: a review of current practice. *Journal of the Association for Vascular Access*. 2013;18(2):93-8.
53. Harwood L, Wilson B, Thompson B, Brown E, Young D. Predictors of hemodialysis central venous catheter exit-site infections. *Canadian Association of Nephrology Nurses and Technologists Journal*. 2008;18(2):26-35.
54. McCann M, Moore Z. Interventions for preventing infectious complications in haemodialysis patients with central venous catheters (review). *The Cochrane Library*. 2010(1).
55. Webster J, Gillies D, O'Riordan E, Sherriff K, Rickard C. Gauze and tape and transparent polyurethane dressings for central venous catheters (review). *The Cochrane Library*. 2011(11).
56. Chin G. CARI Guideline: Prevention of tunnelled dialysis catheter infection. *Kidney Health Australia*. 2012.
57. Scheithauer S, Lewalter K, Schroder J, Koch A, Hafner H, Krizanovic V, et al. Reduction of central venous line-associated bloodstream infection rates by using a chlorhexidine-containing dressing. *Infection*. 2014;42:155-9.
58. Timsit J, Mimoz O, Mourvillier B, Souweine B, Garrouste-Orgeas M, Alfandari S, et al. Randomized controlled trial of chlorhexidine dressing and highly adhesive dressing for preventing catheter-related infections in critically ill adults. *American Journal of Respiratory and Critical Care Medicine*. 2012;186(12):1272-8.
59. Safdar N, O'Horo J, Ghufran A, Bearden A, Didier M, Chateau D, et al. Chlorhexidine-impregnated dressing for prevention of catheter-related bloodstream infection: a meta-analysis. *Critical Care Medicine*. 2014;42(7):1703-13.
60. Weinstein S, Hagle M. *Plumer's principles and practice of infusion therapy* (9th edition). Philadelphia, PA: Lippincott Williams & Wilkins; 2014.
61. Petree C, Wright D, Sanders V, Killion J. Reducing blood stream infections during catheter insertion. *Radiologic Technology*. 2012;83(6):532-40.
62. Lopez-Vargas P, Polkinghorne K. CARI Guideline: Nursing care of central venous catheters. *Kidney Health Australia*. 2012.
63. Lok C, Mokrzycki M. Prevention and management of catheter-related infection in hemodialysis patients. *Kidney International*. 2011;79:587-98.

64. Bilir A, Yelken B, Erkan A. Chlorhexidine, octenidine or providone iodine for catheter related infections: a randomized controlled trial. *Journal of Research in Medical Sciences*. 2013;18(6):510-2.
65. Ullman A, Cooke M, Gillies D, Marsh N, Daud A, McGrail M, et al. Optimal timing for intravascular administration set replacement (review). *The Cochrane Library*. 2013(9).
66. Chong L, Chow Y, Kong S, Ang E. Maintenance of patency of central venous access devices by registered nurses in an acute ambulatory setting: an evidence utilisation project. *International Journal of Evidence Based Healthcare*. 2013;11(1):20-5.
67. Jarvis W. Choosing the best design for intravenous needleless connectors to prevent healthcare-associated bloodstream infections. *Infection Control Today*. 2010;14(8).
68. Jarvis W, Murphy C, Hall K, Fogle P, Karchmer T, Harrington G, et al. Health care-associated bloodstream infections associated with negative- or positive-pressure or displacement mechanical valve needleless connectors. *Clinical Infectious Diseases*. 2009;49:1821-7.
69. Btaiche I, Kovacevich D, Khalidi N, Papke L. The effects of needleless connectors on catheter-related bloodstream infections. *American Journal of Infection Control*. 2011;39(4):277-83.
70. Sona C, Prentice D, Schallom L. National survey of central venous catheter flushing in the intensive care unit. *American Association of Critical-Care Nurses*. 2012;32(1):e12-e9.
71. Australian and New Zealand Society of Blood Transfusion Ltd. Guidelines for the administration of blood products, 2nd edition. Royal College of Nursing, Australia; 2011.
72. Baxter Healthcare Pty Ltd. Correct intravenous practices. Email to Communicable Diseases and Infection Management (CDIM_Infection_Management@health.qld.gov.au) 2014 Dec 1.
73. O'Connell D. Findings of inquest into the death of Ruby Yan Chen. Office of the State Coroner, Queensland Courts. 2014.
74. ACSQHC. National recommendations for user-applied labelling of injectable medicines, fluids and lines. Australian Commission on Safety and Quality in Health Care; 2012.
75. Sandora T, Graham D, Conway M, Dodson B, Potter-Bynoe G, Margossian S. Impact of needleless connector change frequency on central line-associated bloodstream infection rate. *American Journal of Infection Control*. 2014;42:485-9.
76. Halm M, Hickson T, Stein D, Tanner M, VandeGraaf S. Blood cultures and central catheters: is the "easiest way" best practice? *American Journal of Critical Care*. 2011;20:335-8.
77. Mermel L, Allon M, Bouza E, Craven D, Flynn P, O'Grady N, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*. 2009;49:1-45.
78. Pfenninger J, Fowler G. Drawing blood cultures. In: Pfenninger J, Fowler G, editors. *Pfenninger and Fowler's Procedures for Primary Care*, third edition. Philadelphia, PA: Elsevier Mosby; 2011.
79. Septimus E. Clinician guide for collecting cultures. Centers for Disease Control and Prevention. 2014.
80. Heney C. Pathology Queensland/CHRISP recommendations for blood culture collections - adults. Queensland Health; 2014.

81. Health Protection Scotland. Targeted literature review: what are the key infection prevention and control recommendations to inform a prevention of blood culture contamination quality improvement tool? Version 2.0: September 2014.
82. Kim N, Kim M, Lee S, Yun N, Kim K, Park S, et al. Effect of routine sterile gloving on contamination rates in blood culture: a cluster randomized trial. *Annals of Internal Medicine*. 2011;154(3):145-51.
83. Self W, Speroff T, Grijalva C, McNaughton C, Ashburn J, Liu D, et al. Reducing blood culture contamination in the emergency department: an interrupted time series quality improvement study. *Academic Emergency Medicine*. 2013;20:89-97.
84. Self W, Mickanin J, Grijalva C, Grant F, Henderson M, Corley G, et al. Reducing blood culture contamination in community hospital emergency departments: a multicenter evaluation of a quality improvement intervention. *Academic Emergency Medicine*. 2014;21(3):274-82.
85. Dawson S. Blood culture contaminants. *Journal of Hospital Infection*. 2014;87:1-10.
86. Caldeira D, David C, Sampaio C. Skin antiseptics in venous puncture-site disinfection for prevention of blood culture contamination: systematic review with meta-analysis. *Journal of Hospital Infection*. 2011;77:223-32.
87. Maiwald M, Chan E. The forgotten role of alcohol: a systematic review and meta-analysis of the clinical efficacy and perceived role of chlorhexidine in skin antisepsis. *PLoS One*. 2012;7(9).
88. Maiwald M, Chan E. Pitfalls in evidence assessment: the case of chlorhexidine and alcohol in skin antisepsis. *Journal of Antimicrobial Chemotherapy*. 2014;69(8):2017-21.
89. Washer L, Chenoweth C, Kim H, Rogers M, Malani A, Riddell J, et al. Blood culture contamination: a randomized trial evaluating the comparative effectiveness of 3 skin antiseptic interventions. *Infection Control and Hospital Epidemiology*. 2013;34(1):15-21.
90. Harper J. Culture of tips and related devices (Pathology Queensland). Queensland Health; 2014.
91. Rajpurkar M, McGrath E, Joyce J, Boldt-MacDonald K, Chitlur M, Lusher J. Therapeutic and prophylactic ethanol lock therapy in patients with bleeding disorders. *Haemophilia*. 2014;20:52-7.
92. Tan M, Lau J, Guglielmo B. Ethanol locks in the prevention and treatment of catheter-related bloodstream infections. *Annals of Pharmacotherapy*. 2014;48(5):607-15.
93. Huang F, Abrahm J. Chapter 89: Indwelling access devices. In: Hoffman R, Benz E, Silberstein L, Heslop H, Weitz J, Anastasi J, editors. *Hematology: Basic principles and practice* (6th edition). Philadelphia, PA: Elsevier Saunders; 2013.
94. Kaufman J. Chapter 7: Upper extremity, neck and central thoracic veins. In: Kaufman J, Lee M, editors. *Vascular and interventional radiology* (2nd edition). Philadelphia, PA: Elsevier Saunders; 2014.
95. Newsome J, Tisnado J. Chapter 15: Catheter and port removal: techniques and follow-up care. In: Pieters P, Tisnado J, Mauro M, editors. *Venous catheters: a practice manual*. New York, NY: Thieme; 2011.
96. Kandarpa K, Machan L. *Handbook of interventional radiologic procedures*. Philadelphia, PA: Lippincott Williams & Wilkins; 2011.

97. FDA Drug Safety communication: FDA requests label changes and single-use packaging for some over-the-counter topical antiseptic products to decrease risk of infection. U.S. Food and Drug Administration; 2013. Available from <http://www.fda.gov/downloads/Drugs/DrugSafety/UCM374870.pdf>

Bibliography

1. Australia. Australian Council for Safety and Quality in Health Care. National Strategy to Address Health Care Associated Infection: 2003.
2. Bernath V. Tourniquets in phlebotomy. Australia: Monash University: 2006.
3. Australia. NSW Health. Cancer Institute NSW CI-SCaT. Central Venous Access Devices: 2005.
4. Australia. Queensland Health. Queensland Health Pathology and Scientific Services. 2005 Pathology Manual: 2005.
5. Australia. The Canberra Hospital. Lever D, Dahler A, Boland M. Central Venous Catheter Manual: 2005.
6. Australia. The Royal College of Pathologists of Australasia (RCPA). The RCPA Manual Version 4.0: 2004. Available from: <http://www.rcpamanual.edu.au>
7. Canada. Registered Nurses Association of Ontario. Nursing Best Practice Guideline. Care and Maintenance to Reduce Vascular Access Complications: April 2005.
8. United States. Centers for Disease Control and Prevention. Guidelines for the Prevention of Intravascular Catheter-Related Infections: 2011.
9. Crnich C, Maki D. The Promise of Novel Technology for the Prevention of Intravascular Device-Related Bloodstream Infection. I. Pathogenesis and Short-Term Devices. *Healthcare Epidemiology* 2002; 34: 1232-1242.
10. Crnich C, Maki D. The Promise of Novel Technology for the Prevention of Intravascular Device-Related Bloodstream Infection. II. Long-Term Devices. *Healthcare Epidemiology* 2002; 34: 1362-1368.
11. Crowley J. Vascular Access. *Techniques in Vascular and Interventional Radiology* 2003; 6(4): 176-181.
12. Dudrick S. History of Vascular Access. *Journal of Parenteral and Enteral Nutrition* 2006; 30(1): S47-S56.
13. Ewenstein B, Valentino L, Journeycake J, Tarantino M, Shapiro A, Blanchette S, Hoots W, Buchanan G, Manco-Johnson M, Rivard G, Miller L, Geraghty S, Maahs J, Stuart R, Dunham T, Navickis R. Consensus recommendations for the use of central venous devices in haemophilia. *Haemophilia* 2004; 10(5): 629-648.
14. Fellowes C, Kerstein R, Clark J, Azadian B. MRSA on tourniquets and keyboards. *Journal of Hospital Infection* 2006; 64(1): 87-88.
15. Forseter G, Joline C, Wormser G. Blood contamination of tourniquets used in routine phlebotomy. *American Journal of Infection Control* 1990; 18(8): 389-390.
16. Frey A, Schears G. Why Are We Stuck on Tape and Suture?: A Review of Catheter Securement Devices. *Journal of Infusion Nursing* 2006; 29(1): 34-38.

17. Galloway S, Bodenham A. Long-term central venous access. *British Journal of Anaesthesia* 2004; 92(5): 722-734.
18. Ganeshan A, Warakaulle D, Uberoi R. Central Venous Access. *Cardio Vascular and Interventional Radiology* 2007; 30: 26-33.
19. Gillies D, O’Riordan L, Wallen M, Morrison A, Rankin K, Nagy S. Optimal timing for intravenous administration set replacement. *The Cochrane Database of Systematic Reviews* 2005, Issue 4. Art. No.: CD003588.pub2. DOI: 10.1002/14651858.CD003588.pub2.
20. Gillies D, O’Riordan L, Wallen M, Rankin K, Morrison A & Nagy S. Timing Of Intravenous Administration Set Changes: A Systematic Review. *Infection Control and Hospital Epidemiology* 2004; 25(3): 240-250.
21. Grant J. Anatomy and Physiology of Venous System Vascular Access: Implications. *Journal of Parenteral and Enteral Nutrition* 2006; 30(1): S7-S12.
22. Guidelines on Paediatric Parenteral Nutrition. Chapter 9. Venous Access. *Journal of Pediatric Gastroenterology and Nutrition* 2005; 41: S54-62.
23. Hadaway L. Prevent occlusions with these flushing pointers. *Nursing* 2003; 33(1): 28.
24. Infusion Nurses Standards of Practice. *Journal of Infusion Nursing* 2006; 29(1) (Supplement): S1-S62.
25. Isaacman D, Karasic R. Lack of effect of changing needles on contamination of blood cultures. *The Pediatric Infectious Disease Journal* 1990; 9(4): 274-278.
26. Lyon S. Vascular Access Devices and the Oncology Patient. *Cancer Forum* 2005; 29(3): 140-144.
27. Moureau N. Vascular Access Devices. *Nursing* 2001; 31(7): 52-55.
28. Playford E, Looke D, Whitby M, Stackelroth J, Harrison K, Watts A. Endemic Nosocomial Gram-negative Bacteraemias Resulting from Contamination of Intravenous Heparin Infusions. *Journal of Hospital Infection* 1999; 42(1): 21-26.
29. Pratt RJ, Pellowe C, Loveday HP, Robinson N, Smith G, Barrett S, Davey P, Loveday C, McDougall C, Mulhall A, Privett S, Smales C, Taylor L, Weller B, Wilcox MI. The epic Project: Developing National Evidence-based Guidelines for Preventing Healthcare Associated Infections. Guidelines for preventing infections associated with the insertion and maintenance of central venous catheters. *Journal of Hospital Infection*, 2001; 47 (Supplement): S47-S67.
30. Pratt R, Pellowe C, Wilson J, Loveday H, Harper P, Jones S, McDougall C, Wilcox M. epic2 National Evidence-Based Guidelines for Preventing Healthcare-Associated Infections in NHS Hospitals in England. *Journal of Hospital Infection* 2007; 65S: S1-S64.
31. Rickard C, Lipman J, Courtney M, Siversen R, Daley P. Routine Changing Of Intravenous Administration Sets Does Not Reduce Colonization Or Infection In Central Venous Catheters. *Infection Control and Hospital Epidemiology* 2004; 25(8): 650-655.
32. Rosenthal K. Pinpointing intravascular device infections. *Nursing Management* 2003; 34(6): 35-43.
33. Rosenthal K. Optimal infusion therapy? Overcome occlusions. *Nursing Management* 2002; 33(2): 49-50.
34. Rourke C, Bates C, Read R. Poor hospital infection control practice in venepuncture and the use of tourniquets. *Journal of Hospital Infection* 2001; 49: 59-61.

35. Rubinson L, Wu A, Haponik E, Diette G. Why Is It That Internists Do Not Follow Guidelines For Preventing Intravascular Catheter Infections? *Infection Control and Hospital Epidemiology* 2005; 26(6): 525-533.
36. Sacar S, Turgut H, Kaleli I, Cevahir N, Asan, Sacar M, Tekin K. Poor hospital infection control practice in hand hygiene, glove utilization, and usage of tourniquets. *American Journal of Infection Control* 2006; 34(9): 606-609.
37. Safdar N, Maki D. Inflammation at the insertion site is not predictive of catheter-related bloodstream infection with short-term, noncuffed central venous catheters. *Critical Care Medicine* 2002; 30(12): 2632-2635.
38. Sansivero G. Venous Anatomy and Physiology: Considerations for Vascular Access Device Placement and Function. *Journal of Infusion Nursing* 1998; 21(5S): S107-S114.
39. United States. Infection Control Today. Hanchett M. Needleless Connectors and Bacteremia: Is There a Relationship? [online] 1 November 2005. Available from: http://www.infectioncontrolday.com/articles/410/410_5b1feat2.html (Internet Access Required)
40. United States. Infection Control Today. Schmidt M. Preventing Intravenous Catheter-Associated Infections: An Update: 2001.
41. United Kingdom. National Patient Safety Agency. Learning through action to reduce infection: 2006.
42. United States. eMedicine. Larson S, Hebra A. Vascular Access: A Surgical Perspective: 2006. Available from: <http://www.emedicine.com/ped/topic3050.htm> (Internet Access Required)
43. United States. Institute for Healthcare Improvement (IHI). Getting Started Kit: Prevent Central Line Infections. How-to Guide: 2006. Available from: <http://www.ihl.org/IHI/Programs/Campaign/> (Internet Access Required)
44. Waitt C, Waitt P, Pirmohamed M. Intravenous therapy. *Postgrad Med J* 2004; 80: 1-6.
45. Basford T, Poenaru D, Silva M. Comparison of Delayed Complications of Central Venous Catheters Placed Surgically or Radiologically in Pediatric Oncology Patients. *Journal of Pediatric Surgery* 2003; 38(5): 788-792.
46. Fry W, Clagett G, O'Rourke T. Ultrasound-Guided Central Venous Access. *Archives of Surgery* 1999; 134: 738-741.
47. Kuter D. Thrombotic Complications of Central Venous Catheters in Cancer Patients. *The Oncologist* 2004; 9: 207-216.
48. Gilbert D, Dworkin R, Raber S, Leggett J. Outpatient Parenteral Antimicrobial-Drug Therapy. *The New England Journal of Medicine* 1997; 337(12): 830-838.
49. Lau K. Percutaneous Insertion of Hickman Central Venous Catheter: Jugular Approach. *J HK Coll Radiol*, 2002; 5: 69-721.
50. Lyon S. Vascular Access Devices and the Oncology Patient. *Cancer Forum* 2005; 29(3): 140-144.
51. Macdonald S, Watt A, McNally D, Edwards R, Moss J. Comparison of Technical Success and Outcome of Tunneled Catheters Inserted via the Jugular and Subclavian Approaches. *Journal of Vascular and Interventional Radiology* 2000; 11: 225-231.

52. Moller T, Borregaard N, Tvede M, Adamsen L. Patient education – a strategy for prevention of infections caused by permanent central venous catheters in patients with haematological malignancies: a randomized clinical trial. *Journal of Hospital Infection* 2005; 61: 330-341.
53. Olson K, Rennie R, Hanson J, Ryan M, Gilpin J, Falsetti M, Heffner T, Gaudet S. Evaluation of a No-dressing Intervention for Tunneled Central Venous Catheter Exit Sites. *Journal of Infusion Nursing* 2004; 27(1): 37-44.
54. Raymond P, Onders M, Shenk R, Thomas A, Stellato M. Long-term central venous catheters: size and location does matter. *The American Journal of Surgery* 2006; 191: 396-399.
55. Silberzweig J, Sacks D, Khorsandi A, Bakal C and the members of the Society of Interventional Radiology Technology Assessment Committee. *Journal of Vascular and Interventional Radiology* 2003; 11: 391-400.
56. United Kingdom. British Committee for Standards in Haematology (BCSH). BCSH Guidelines on the Insertion and Management of Central Venous Access Devices: 2006.
57. United Kingdom. Christie Hospital, National Health Service (NHS) Trust. Care of your central venous catheter. A guide for patients and their carers: 2005.
58. Venous Access. *Journal of Pediatric Gastroenterology and Nutrition* 2005; 41: S54-S62.

5. Definitions of terms used in the policy and supporting documents

Term	Definition / Explanation / Details	Source
Central line associated blood stream infection (CLABSI) / Catheter-related bacteraemia	Blood cultures are positive for the presence of bacteria with or without the accompanying symptom of fever, and no apparent source for the infection other than the catheter.	NKF K/DOQI, 2006 ⁽²⁴⁾
Exit-site infection	Inflammation (erythema, warmth, tenderness, induration within 2cm of the exit site) or purulence, confined to the area surrounding the catheter exit site, not extending superiorly beyond the cuff if the catheter is tunnelled, with exudate confirmed to be positive by microscopy/culture and no systemic symptoms or positive blood cultures.	NKF K/DOQI, 2006 ⁽²⁴⁾
Healthcare Associated Infection (HAI)	Healthcare associated infections (HAI) are those infections that are not present or incubating at the time of admission to a healthcare program or facility, but develop within a healthcare organisation, or are produced by micro-organisms acquired during admission.	ACSQHC ⁽²⁾
Non-sterile antiseptic applicators (e.g. swabsticks)	Topical antiseptic applicators containing antiseptic solution (e.g. isopropyl alcohol, chlorhexidine gluconate). These applicators are single use only and are not usually manufactured as sterile products. Refer to manufacturer's recommendations and labelling.	U.S. Food and Drug Administration ⁽⁹⁷⁾
Tunnel infection	Tunnel infection is a process of suppuration or erythema, tenderness and induration in the tissues overlying the catheter more than 2cm from the exit site.	NKF K/DOQI, 2006 ⁽²⁴⁾

6. Document approval details

Document custodian

Dr Heidi Carroll, Senior Medical Officer, Communicable Diseases Branch

Approval officer

Dr Sonya Bennett, Executive Director, Communicable Diseases Branch

Approval date: 10 June 2015

Review date: 10 June 2018

7. Version Control

Version	Date	Prepared by	Comments
1.0	2012	CHRISP	[QH-GDL-321-6-3:2012] Rescinded
2.0	March 2013	CHRISP	
3.0	January 2015	CDIM	